| HTS | High-throughput screening |
| VDR | Vitamin D receptor: NR1I1 |
| AF-1 | Activation function 1 |
| Zn | Zinc |
| DBD | DNA-binding domain |
| NLS | Nuclear localization signal |
| LBD | Ligand-binding domain |
| AF-2 | Activation function 2 |
| ER | Estrogen receptor, ERα: NR3A1, ERβ: NR3A2 |
| AR | Androgen receptor: NR3C4 |
| RXR | Retinoid X receptor, RXRα: NR2B1, RXRβ: NR2B2, RXRγ: NR2B3 |
| PPIs | Protein–protein interactions |
| HSP | Heat shock protein |
| NMR | Nuclear magnetic resonance |
| SPR | Surface plasmon resonance |
| LOPAC | Library of Pharmacologically Active Compounds |
| PPAR | Peroxisome proliferator activated receptor, PPARα: NR1C1, PPARβ/δ: NR1C2, and PPARγ: NR1C3 |
| T2D | Type 2 diabetes |
| PSCs | Pluripotent stem cells |
| Em | Embryonic |
| ExEm | Extraembryonic |
| LNCaP | Lymph Node Carcinoma of the prostate |
| TNF | Tumor Necrosis Factor |
| NF | Nuclear factor |
| GFP | Green fluorescence protein |
| NIH | National Institutes of Health |
| FXR | Farnesoid X receptor, FXR: NR1H4, FXRβ: NR1H5 |
| FRET | Fluorescence resonance energy transfer |
| FDA | Food and Drug Administration |
| SBDD | Structure-based drug discovery |
| NCATS | National Center for Advancing Translational Sciences |
| NCGC | NCATS Chemical Genomics Center (NCGC) |
| ELF | European Lead Factory |
| SMEs | Small and medium enterprises |
| CNCL | Chinese National Compound Library |
| DDI | Drug Discovery Initiative |
| BINDS | Basis for Supporting Innovative Drug Discovery and Life Science Research |
| CAR | Constitutive androstane receptor: NR1I3 |
| GR | Glucocorticoid receptor: NR3C1 |
| LXR | Liver X receptor, LXRα: NR1H3, LXRβ: NR1H2 |
| PR | Progesterone receptor: NR3C3 |
| PXR | Pregnane X receptor: NR1I2 |
| RAR | Retinoic acid receptor, RARα: NP1B1, RARβ: NP1B2, RARγ: NR1B3 |
| TR | Thyroid hormone receptor, TRα: NP1A1, TRβ: NP1A2 |